Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Jose Antonio Gastelum
Jose Antonio Gastelum

Vertex Pharmaceuticals enters new reimbursement agreement for cystic fibrosis therapy after stock ends session up 1%

Vertex Pharmaceuticals enters new reimbursement agreement for cystic fibrosis therapy after stock ends session up 1%
Vertex Pharmaceuticals stock rises 1% today

Vertex Pharmaceuticals has secured a reimbursement agreement for its recent cystic fibrosis therapy in Latvia. The stock is up 1% on the day at $553.04.

VRTX price prediction
24H -1.26%
$498.29
48H -1.58%
$496.65
7D -2.28%
$493.13
1M -2%
$494.55
3M 3.19%
$520.74
6M 17.84%
$594.68
12M 32.82%
$670.27
Detailed
Current price: $504.63 4.97 0.99%
Real-time Data 13:15
Daily range 497.73 Arrow from to Icon 511.34
Weekly range 484.99 Arrow from to Icon 517.12
Loading...

Highlights

  • Vertex Pharmaceuticals secured reimbursement for its new cystic fibrosis therapy in Latvia, enabling broad patient access from age 6 and above.
  • Vertex Pharmaceuticals stock is up 1% on the day at $553.04 with 100 of 124 analysts rating it a buy.
  • Vertex stock trades at 28.9 times trailing earnings and a forward multiple of 22.9, with a market value near $125.73 billion.

Vertex Pharmaceuticals has entered a new reimbursement agreement for its latest cystic fibrosis therapy in Latvia. The agreement enables broad access for eligible people living with cystic fibrosis ages 6 and older. Broad access under the agreement has been available since August 17, 2026.

Gains slow as price tests resistance with rally near overbought levels

Price is sitting right at resistance from the weekly high at $555.69. The advance aligns with a sustained bullish structure on the daily chart, as shares of Vertex Pharmaceuticals continue to hold above the MA-20, MA-50, and MA-200. An RSI reading at 66.6 shows the rally is nearing overbought territory, suggesting limited room for further gains in the immediate term.

Odds favor upside as traders await a close above the weekly high

To gauge whether the move is gaining traction, traders should watch for a decisive close above $555.69. Vertex Pharmaceuticals stock is currently testing resistance from the weekly high, but has yet to break through that level. Even so, despite a firm trend higher over the past week, the next five trading days carry a 78% probability of upside versus a 22% probability of downside, with an expected range between $542.69 and $563.38. A close above $555.69 would show buyers are willing to follow through, while a drop below $532.55 would indicate the advance is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Previously it was reported that Vertex Pharmaceuticals extended a reimbursement agreement in Uruguay, contributing to a constructive technical outlook for the stock. The latest agreement in Latvia expands European access and reinforces the ongoing bullish structure, with traders advised to watch for a decisive close above $555.69 as a signal for potential further gains.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Who is Richard Heart, the HEX founder wanted by Interpol?
  • By Olena Litvinenko
  • 6 hours ago
Who is Richard Heart, the HEX founder wanted by Interpol?
Editors' Picks
Kaiko CEO: European stablecoins still cannot compete with USDT
  • By Eugene Komchuk
  • 8 hours ago
Kaiko CEO: European stablecoins still cannot compete with USDT
Editors' Picks
Adobe and AI: Is the creative software giant losing its edge?
  • By Dmytro Kharkov
  • 10 hours ago
Adobe and AI: Is the creative software giant losing its edge?
Editors' Picks
All Editors' Top Picks

Latest Vertex Pharmaceuticals News

Vertex Pharmaceuticals announces $10 billion acquisition: Can VRTX reverse weak momentum?
  • By Jainam Mehta
  • 13.10.2026
Vertex Pharmaceuticals announces $10 billion acquisition: Can VRTX reverse weak momentum?
Stocks
#Forecast #Vertex Pharmaceuticals
VRTX drops as $10B Crinetics Pharmaceuticals acquisition raises risk
  • By Anton Kharitonov
  • 01.10.2026
VRTX drops as $10B Crinetics Pharmaceuticals acquisition raises risk
Stocks
#Forecast #Vertex Pharmaceuticals
Vertex Pharmaceuticals enters reimbursement agreement for cystic fibrosis therapy after muted trading session
  • By Hlib Chabaniuk
  • 23.09.2026
Vertex Pharmaceuticals enters reimbursement agreement for cystic fibrosis therapy after muted trading session
Companies
#Vertex Pharmaceuticals
All Vertex Pharmaceuticals News
  • Olena Litvinenko
  • 6 hours ago
Who is Richard Heart, the HEX founder wanted by Interpol?
  • Eugene Komchuk
  • 8 hours ago
Kaiko CEO: European stablecoins still cannot compete with USDT
  • Dmytro Kharkov
  • 10 hours ago
Adobe and AI: Is the creative software giant losing its edge?
  • Pavlo Kot
  • Yesterday
Solana vs. Base: Who will dominate the token launch market?
  • Pavlo Kot
  • 17.10.2026
Jobs in crypto: Which specialists are in demand now?
  • Yulia Slavina
  • 15 min ago
Amit Kukreja: Anthropic plans to give 20% of company shares to public, Elon Musk offers $10B in SPCX shares to U.S. children
  • Elena Nikulina
  • 24 min ago
Dogecoin opportunity was missed in a comical way, Zack Nelson states
  • Yaroslav Dmytrenko
  • 30 min ago
Traffic should be free until it is unsustainable, Alex Bosworth notes
  • Oksana Koneva
  • 54 min ago
Ross Gerber: Earnings season brings expectations of 30% increase over estimates
  • Eugene Komchuk
  • 1 hour ago
Caitlin Long: First loan P&I payment to be settled using HazelNetwork tokenized deposit in Dallas event
Top News
  • Ivan Andriyenko
  • 3 hours ago
Canada inflation comes in below forecasts ahead of central bank decision
Canada inflation comes in below forecasts ahead of central bank decision
  • Eugene Komchuk
  • 4 hours ago
Trump family's stablecoin loses $400 million in market capitalization
Trump family's stablecoin loses $400 million in market capitalization
  • Olga Shendetskaya
  • 5 hours ago
Indonesia tightens stock market rules to address MSCI concerns
Indonesia tightens stock market rules to address MSCI concerns
  • Eugene Komchuk
  • 8 hours ago
Kaiko CEO: European stablecoins still cannot compete with USDT
Kaiko CEO: European stablecoins still cannot compete with USDT
  • Eugene Komchuk
  • 9 hours ago
JPMorgan launches JPM Coin token on Ethereum
JPMorgan launches JPM Coin token on Ethereum
Live News
  • Anton Kharitonov
  • Now
EUR/USD holds near 1.1230 as ECB and Fed expectations weigh on currency amid Treasury yield stability
  • Mykhailo Ihnatenko
  • Now
Nvidia stock tests $217 as AI infrastructure worries pressure tech sector
  • Parshwa Turakhiya
  • Now
Crypto.com and Novig challenge Missouri sports betting restrictions
  • Igor Krasulya
  • Now
French bond yields face pressure as unrest threatens budget plans
  • Mykhailo Ihnatenko
  • Now
Ethereum price prediction: Can ETH break $2,440 before another liquidation wave?
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers